Islet Cell Transplant Clinical Trial for Type 1 Diabetes

A Chicago clinical trial is testing transplanted islet cells from a cadaver into the liver to produce insulin in people with type 1 diabetes. Participant Katie Beth and diabetes expert Dr. Michael Via discuss the trial's approach, early results, and the use of an anti-rejection drug.

■ Clinical trial approach
- Islet cells from a cadaver are transplanted into the liver to make insulin.
- Participants receive the anti-rejection drug TGO Prart every three weeks.

■ Participant and expert perspectives
- Katie Beth describes treatment side effects and makes a 1,300-mile round trip for care.
- Dr. Michael Via, not involved in the trial, comments on the results and the search for a type 1 diabetes cure.

Viewers interested in type 1 diabetes research, clinical trials, and transplant-based treatments can learn about one trial's approach and the role of anti-rejection medication. Full clinical data, long-term outcomes, and medical advice are not included.